MARKET

LJPC

LJPC

La Jolla Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.21
+0.04
+0.56%
After Hours: 7.15 -0.06 -0.83% 19:54 05/22 EDT
OPEN
7.16
PREV CLOSE
7.17
HIGH
7.25
LOW
7.01
VOLUME
334.18K
TURNOVER
--
52 WEEK HIGH
13.90
52 WEEK LOW
2.300
MARKET CAP
196.82M
P/E (TTM)
-2.0951
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LJPC stock price target is 13.75 with a high estimate of 20.00 and a low estimate of 4.000.

EPS

LJPC News

More
How La Jolla (LJPC) Stock Stands Out in a Strong Industry
Zacks · 4d ago
Melinta enters the fray for Tetraphase Pharma with takeover bid
Seeking Alpha - Article · 05/15 11:40
Tetraphase Says On May 12 Received Revised Proposal From La Jolla Pharmaceutical For $22.3M In Cash Plus Additional $12.5M In Cash Under Contingent Value; Co.'s Board At This Time Continues To Recommend AcelRx Merger Agreement
As previously disclosed, on May6, 2020, Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) received an unsolicited proposal from La Jolla Pharmaceutical Company (“La Jolla”) to acquire Tetraphase
Benzinga · 05/13 10:23
La Jolla's Path Forward
Seeking Alpha - Article · 05/08 23:49
Tetraphase: A Bidding War Shareholders Shouldn't Wait Around For
Seeking Alpha - Article · 05/08 15:09
Bidding War Sends Tetraphase Shares Soaring
Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.Two-way Race The Watertown, Mass
Benzinga · 05/07 16:55
Bidding War Sends Tetraphase Shares Soaring
Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.
Benzinga · 05/07 16:55
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.)
Benzinga · 05/07 11:42

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About LJPC

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
More

Webull offers kinds of La Jolla Pharmaceutical Company stock information, including NASDAQ:LJPC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LJPC stock news, and many more online research tools to help you make informed decisions.